Oncolytics Biotech Has Entered Into An Agreement With Leede Jones Gable As Underwriter And Book-runner To Purchase, On A Bought-deal Basis, 6,667,000 Units For Gross Proceeds Of $15M At $2.25/Unit
Oncolytics Biotech Has Entered Into An Agreement With Leede Jones Gable As Underwriter And Book-runner To Purchase, On A Bought-deal Basis, 6,667,000 Units For Gross Proceeds Of $15M At $2.25/Unit
Oncolytics Biotech 已與作爲承銷商和賬簿管理人的 Leede Jones Gable 達成協議，以收購協議的方式購買666.7萬套，總收益爲1500萬美元，每單位2.25美元
Oncolytics Biotech Has Entered Into An Agreement With Leede Jones Gable As Underwriter And Book-runner To Purchase, On A Bought-deal Basis, 6,667,000 Units For Gross Proceeds Of $15M At $2.25/Unit
Oncolytics Biotech 已與作爲承銷商和賬簿管理人的 Leede Jones Gable 達成協議，以收購協議的方式購買666.7萬套，總收益爲1500萬美元，每單位2.25美元
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。